Altimmune, Inc. (NASDAQ:ALT – Get Free Report)’s stock price fell 8.1% during mid-day trading on Tuesday after HC Wainwright lowered their price target on the stock from $15.00 to $12.00. HC Wainwright currently has a buy rating on the stock. Altimmune traded as low as $9.38 and last traded at $9.40. 509,332 shares changed hands during trading, a decline of 91% from the average session volume of 5,962,100 shares. The stock had previously closed at $10.23.
Other equities analysts also recently issued research reports about the stock. B. Riley reissued a “buy” rating and issued a $20.00 price objective on shares of Altimmune in a research note on Thursday, March 28th. The Goldman Sachs Group assumed coverage on Altimmune in a research report on Wednesday, January 24th. They set a “neutral” rating and a $13.00 price target on the stock.
Hedge Funds Weigh In On Altimmune
A number of large investors have recently made changes to their positions in the business. Barclays PLC boosted its holdings in Altimmune by 62.0% in the third quarter. Barclays PLC now owns 180,409 shares of the company’s stock valued at $470,000 after purchasing an additional 69,014 shares during the last quarter. GSA Capital Partners LLP lifted its stake in Altimmune by 153.1% in the 3rd quarter. GSA Capital Partners LLP now owns 445,868 shares of the company’s stock worth $1,159,000 after purchasing an additional 269,676 shares in the last quarter. Dark Forest Capital Management LP lifted its stake in Altimmune by 13.4% in the 3rd quarter. Dark Forest Capital Management LP now owns 230,353 shares of the company’s stock worth $599,000 after purchasing an additional 27,210 shares in the last quarter. Keudell Morrison Wealth Management purchased a new position in Altimmune in the 3rd quarter worth approximately $36,000. Finally, WealthPlan Investment Management LLC purchased a new stake in shares of Altimmune during the 3rd quarter valued at approximately $31,000. 78.05% of the stock is owned by institutional investors and hedge funds.
Altimmune Stock Performance
The company’s 50-day moving average price is $9.93 and its 200 day moving average price is $6.88. The stock has a market cap of $502.38 million, a PE ratio of -5.65 and a beta of 0.05.
About Altimmune
Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company’s lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and non-alcoholic steatohepatitis.